2-cyano-N-[3,4-(difluoro)phenyl]acetamide | 541519-41-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-cyano-N-[3,4-(difluoro)phenyl]acetamide
• 英文别名: 2-cyano-N-(3,4-difluorophenyl)acetamide
• CAS: 541519-41-9
• 化学式: C₉H₆F₂N₂O
• 分子量: 196.156
• InChiKey: NNNLNPCGSUYAKL-UHFFFAOYSA-N

物化性质

• 沸点：
  385.9±42.0 °C(Predicted)
• 密度：
  1.392±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  52.9
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2926909090

反应信息

• 作为反应物：
  描述：

  2-cyano-N-[3,4-(difluoro)phenyl]acetamide 在 硫酸 、 水 作用下， 以 二乙二醇单甲醚 为溶剂， 反应 25.33h， 生成 1-(3,4-difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxylic acid
  参考文献：
  名称：

  [EN] FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF
  [FR] DÉRIVÉS HÉTÉROCYCLIQUES FUSIONNÉS ET LEUR UTILISATION

  摘要：

  本发明提供了一种具有强烈激酶抑制活性的融合杂环衍生物及其用途。本发明涉及本说明书中所定义的符号表示的化合物，或其盐。

  公开号：

  WO2009136663A1
• 作为产物：
  描述：

  1-氰基乙酰-3,5-二甲基吡唑 、 3,4-二氟苯胺 生成 2-cyano-N-[3,4-(difluoro)phenyl]acetamide
  参考文献：
  名称：

  咪唑并[1,2-b]吡唑-7-甲酰胺的合成、细胞毒性表征和合成孔径雷达研究

  摘要：

  研究了新型咪唑并[1,2-b]吡唑-7-甲酰胺的合成和体外细胞毒特性。在利用 MCF-7 人乳腺、4T1 乳腺和 HL-60 人早幼粒细胞白血病癌细胞系的 2D 和 3D 培养物进行先导优化后，构建了一个 67 元文库，并构建了构效关系（SAR ) 确定。七个合成的类似物表现出亚微摩尔活性，其中化合物 63 发挥最显着的效力，具有显着的 HL-60 敏感性（IC50 = 0.183 μM）。

  DOI：

  10.1002/ardp.201800062

文献信息

• FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF
  申请人：Miyamoto Naoki

  公开号：US20110046169A1

  公开（公告）日：2011-02-24

  The present invention provides a fused heterocyclic derivative having a strong kinase inhibitory activity and use thereof. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.

  本发明提供了一种具有强大的激酶抑制活性的熔合杂环衍生物及其使用。本发明涉及一种由式子所表示的化合物，其中每个符号如本说明书中所定义的，或其盐。
• Fused heterocyclic derivatives and use thereof
  申请人：Miyamoto Naoki

  公开号：US08445509B2

  公开（公告）日：2013-05-21

  The present invention provides a fused heterocyclic derivative having a strong kinase inhibitory activity and use thereof. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.

  本发明提供了一种具有强烈激酶抑制活性的融合杂环衍生物及其使用。本发明涉及一种由下式表示的化合物，其中每个符号如本说明书所定义，或其盐。
• Low Molecular Weight Amidoximes that Act as Potent Inhibitors of Lysine-Specific Demethylase 1
  作者：Stuart Hazeldine、Boobalan Pachaiyappan、Nora Steinbergs、Shannon Nowotarski、Allison S. Hanson、Robert A. Casero、Patrick M. Woster

  DOI：10.1021/jm3002845

  日期：2012.9.13

  The recently discovered enzyme lysine-specific demethylase 1 (LSD1) plays an important role in the epigenetic control of gene expression, and aberrant gene silencing secondary to LSD1 dysregulation is thought to contribute to the development of cancer. We reported that (bis)guanidines, (bis)biguanides, and their urea- and thiourea isosteres are potent inhibitors of LSD1 and induce the re-expression of aberrantly silenced tumor suppressor genes in tumor cells in vitro. We now report a series of small molecule amidoximes that are moderate inhibitors of recombinant LSD1 but that produce dramatic changes in methylation at the histone 3 lysine 4 (H3K4) chromatin mark, a specific target of LSD1, in Calu-6 lung carcinoma cells. In addition, these analogues increase cellular levels of secreted frizzle-related protein (SFRP) 2, H-cadherin (HCAD), and the transcription factor GATA4. These compounds represent leads for an important new series of drug-like epigenetic modulators with the potential for use as antitumor agents.
• 5-Aminothiophene-2,4-dicarboxamide analogues as hepatitis B virus capsid assembly effectors
  作者：Jing Tang、Andrew D. Huber、Dallas L. Pineda、Kelsey N. Boschert、Jennifer J. Wolf、Jayakanth Kankanala、Jiashu Xie、Stefan G. Sarafianos、Zhengqiang Wang

  DOI：10.1016/j.ejmech.2018.12.047

  日期：2019.2

  Chronic hepatitis B virus (HBV) infection represents a major health threat. Current FDA-approved drugs do not cure HBV. Targeting HBV core protein (Cp) provides an attractive approach toward HBV inhibition and possibly infection cure. We have previously identified and characterized a 5-amino-3-methylthiophene-2,4-dicarboxamide (ATDC) compound as a structurally novel hit for capsid assembly effectors (CAEs). We report herein hit validation through studies on absorption, distribution, metabolism and excretion (ADME) properties and pharmacokinetics (PK), and hit optimization via analogue synthesis aiming to probe the structure-activity relationship (SAR) and structure-property relationship (SPR). In the end, these medicinal chemistry efforts led to the identification of multiple analogues strongly binding to Cp, potently inhibiting HBV replication in nanomolar range without cytotoxicity, and exhibiting good oral bioavailability (F). Two of our analogues, 19o (EC50 = 0.11 mu M, CC50 > 100 mu M = 25%) and 19k (EC50 = 0.31 mu M, CC50 > 100 mu M, F = 46%), displayed overall lead profiles superior to reported CAEs 7-10 used in our studies. (C) 2018 Elsevier Masson SAS. All rights reserved.
• US8445509B2
  申请人：——

  公开号：US8445509B2

  公开（公告）日：2013-05-21